Meeting
2014 ASCO Annual Meeting
Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
Authors
Brigitte C. Widemann
Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
Brigitte C. Widemann , Leigh Jessica Marcus , Michael J. Fisher , Brian D. Weiss , AeRang Kim , Eva Dombi , Andrea Baldwin , Patricia Whitcomb , Staci Martin , Andrea Gillespie , Austin Doyle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT01362803
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10018)
DOI
10.1200/jco.2014.32.15_suppl.10018
Abstract #
10018
Poster Bd #
319
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
First Author: Geraldine Helen O'Sullivan Coyne
Poster
2018 ASCO Annual Meeting
Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN).
First Author: Birgit Geoerger
Poster
2018 ASCO Annual Meeting
Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.
First Author: Anthony J. Chalmers
Poster
2017 ASCO Annual Meeting
Phase I study of pexidartinib (PLX3397) in children with refractory leukemias and solid tumors including neurofibromatosis type I (NF1) related plexiform neurofibromas (PN).
First Author: Lauren Hittson